This study is currently not recruiting participants.

OUD (Opioid Use Disorder) Target Trial

  • STATUS
    Not Recruiting
  • End date
    Oct 31, 2026
  • participants needed
    80
  • sponsor
    Duke University
Updated on 9 September 2024

Summary

In this research study the investigators will work with 80-participants with opioid use disorder who are starting treatment with the medication buprenorphine and are trying to quit using opioids.

The investigators are trying to learn two things:

  1. Can an MRI brain marker be used to predict which participants will be successful in quitting opioids with buprenorphine?
  2. Does adjunctive treatment with repetitive Transcranial Magnetic Stimulation (rTMS) help people quit using opioids more than a sham (placebo) version of rTMS?

In order to complete the study the investigators will ask participants to:

  • Complete an MRI within 5-days of starting buprenorphine and again after they are on a full stable dose 1-3 weeks later.
  • Undergo study-treatment with 50-sessions of either real or placebo rTMS in as little as 1-week (10-sessions-per-day for five days) or as long as over 6-weeks.
  • Meet with the investigators once per week over the following 12-weeks to see if the participants have been able to quit using opioids over that time.

Details
Condition Opioid Use Disorder
Age 18years or above
Treatment sham repetitive transcranial magnetic stimulation (rTMS), Active repetitive transcranial magnetic stimulation (rTMS)
Clinical Study IdentifierNCT06585709
SponsorDuke University
Last Modified on9 September 2024

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.